D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
NGM holding history
NGM Biopharmaceuticals Inc in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NGM overviewAll 13F holders of NGMFull Q2 2026 holdings
- Shares (Q1 2024)
- 0
- Sold out in Q1 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2024 | 0 | $0 | 0.0% | −308,104−100.0% | Sold out | Holders |
| Q4 2023 | 308,104 | $264.7K | <0.1% | −14,368−4.5% | Reduced | Holders |
| Q3 2023 | 322,472 | $345.0K | <0.1% | −32,418−9.1% | Reduced | Holders |
| Q2 2023 | 354,890 | $919.2K | <0.1% | +77,816+28.1% | Added | Holders |
| Q1 2023 | 277,074 | $1.13M | <0.1% | +154,118+125.3% | Added | Holders |
| Q4 2022 | 122,956 | $617.2K | <0.1% | −16,301−11.7% | Reduced | Holders |
| Q3 2022 | 139,257 | $1.82M | <0.1% | −21,608−13.4% | Reduced | Holders |
| Q2 2022 | 160,865 | $2.06M | <0.1% | +97,468+153.7% | Added | Holders |
| Q1 2022 | 63,397 | $967.0K | <0.1% | +3,366+5.6% | Added | Holders |
| Q4 2021 | 60,031 | $1.06M | <0.1% | +14,953+33.2% | Added | Holders |
| Q3 2021 | 45,078 | $948.0K | <0.1% | −60−0.1% | Reduced | Holders |
| Q2 2021 | 45,138 | $890.0K | <0.1% | +34,950+343.1% | Added | Holders |
| Q1 2021 | 10,188 | $296.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.